- Flexion Therapeutics continues to report steady revenue growth as ZILRETTA moves deeper into commercialization. Despite the ongoing pandemic, Flexion reported encouraging Q1 earnings.
- ZILRETTA's commercial numbers are improving which has encouraged Flexion's management to reiterate their full-year net sales guidance of $120M-$130M.
- FLXN has been hit by the sector’s sell-off that has crushed many of the small-to-mid-cap biopharma tickers. I believe this unjustified sell-off is an opportunity to reload my FLXN position.
For further details see:
Flexion Therapeutics: Sector Sell-Off Provides Opportunity To Reload At A Discount